Search results
Results from the WOW.Com Content Network
The long-acting injectable form of paliperidone, marketed as Invega Sustenna in the US, [6] and Xeplion in the EU, [12] was approved by the FDA in July 2009. It was initially approved in the European Union in 2007, for schizophrenia, the extended release form and use for schizoaffective disorder were approved in the EU in 2010, and extension to ...
Following is a list of antipsychotics, sorted by class. Antipsychotics. Antipsychotics by class Generic name Brand names Chemical class ATC code
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Depakote (valproic acid/sodium valproate) – an antiepileptic and mood stabilizer used to treat bipolar disorder, neuropathic pain and others; sometimes called an antimanic medication. Depakene is the trade name for the same drug prepared without sodium. Desyrel – an atypical antidepressant used to treat depression and insomnia
Lithium Lithium is the "classic" mood stabilizer, the first to be approved by the US FDA, and still popular in treatment. Therapeutic drug monitoring is required to ensure lithium levels remain in the therapeutic range: 0.6 to 0.8 or 0.8–1.2 mEq/L (or millimolar).
Lumateperone (Caplyta) – In December 2019, lumateperone, a presynaptic D 2 receptor partial agonist and postsynaptic D 2 receptor antagonist, received its first global approval in the US for the treatment of schizophrenia in adults. [168] In 2020 and 2021 FDA approved for depressive episodes associated with bipolar I or II disorder in adults ...
Schizoaffective disorder is a mental disorder characterized by symptoms of both schizophrenia and a mood disorder, either bipolar disorder or depression. [4] [5] The main diagnostic criterion is the presence of psychotic symptoms for at least two weeks without prominent mood symptoms. [5]
Levosulpiride – approved in low doses for major depressive disorder [11] Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression; Lurasidone (Latuda) – approved as a monotherapy for bipolar depression; Quetiapine (Seroquel) – approved as a monotherapy for bipolar depression